| Company Name: | Gen-Probe, Incorporated | | Ticker Symbol: | GPRO | | | WWW Address: | www.gen-probe.com | | CEO: | Carl W. Hull | | No. of Employees: | 991 | | Common Issue Type: | CS | | Business Description: | The Company is engaged in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid probe-based products used for the clinical diagnosis of human diseases and for screening donated human blood.
|
| | | Industry Information: | DIVERSIFIED SERVICES - Research Services [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 42.33 |  -0.09 | 40.64 | 43.9 | 42.61 | 42.70 | 42.25 | 175560 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 2,078.4 | 49.1 | 0.93 | 1.95 | 0.00 | 25.0 | 0.0 | 49.29 - 34.43 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 42.33 | $ | | PE Ratio - LTM | 25.0 | |
| Market Capitalisation | 2,077.8 | mil |
| Latest Shares Outstanding | 49.1 | mil |
| Earnings pS (EPS) | 1.95 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 476,988 | $ |
| Effective Tax Rate | 33.5 | % |
| Float | 49.9 | mil |
| Float as % of Shares Outstanding | 99.2 | % |
| Foreign Sales | 109 | mil |
| Domestic Sales | 363 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 23.70 | % |
| Research & Devlopment (R&D) as % of Revenue | 21.90 | % |
| Gross Profit Margin | 80.1 | % |
| EBITDA Margin | 34.4 | % |
| Pre-Tax Profit Margin | 28.5 | % |
| Assets Turnover | 0.5 | % |
| Return on Assets (ROA) | 8.4 | % |
| Return on Equity (ROE) | 12.1 | % |
| Return on Capital Invested (ROCI) | 12.1 | % |
| Current Ratio | 2.2 | |
| Leverage Ratio (Assets/Equity) | 1.4 | |
| Interest Cover | 92.4 | |
| Total Debt/Equity (Gearing Ratio) | 0.33 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 7.37 | $ |
| Cash pS | 3.19 | $ |
| Book-Value pS | 14.91 | $ |
| Tangible Book-Value pS | 10.37 | $ |
| Cash Flow pS | 2.81 | $ |
| Free Cash Flow pS | -0.82 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 2.84 | |
| Price/Tangible Book Ratio | 4.08 | |
| Price/Cash Flow | 15.1 | |
| Price/Free Cash Flow | -51.4 | |
| P/E as % of Industry Group | 55.0 | % |
| P/E as % of Sector Segment | 12.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 1.5 | 100 | 3,195 | 6,160 |
| 4 Weeks | 42.90 | 40.65 | 41.72 | 1.5 | 95 | 4,534 | 81,616 |
| 13 Weeks | 45.24 | 37.30 | 39.00 | 8.5 | 101 | 5,735 | 355,540 |
| 26 Weeks | 45.24 | 35.70 | 42.63 | -0.7 | 82 | 5,757 | 725,374 |
| 52 Weeks | 49.29 | 34.43 | 36.85 | 14.9 | 93 | 6,007 | 1,501,736 |
| YTD | 49.29 | 35.70 | - | -1.2 | 80 | 6,134 | 1,398,565 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 42.17 | 42.02 | 42.18 | 41.42 | 42.25 | 0.93 | 0.90 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 14.36 | 96.1 | 10.44 |
| Income | 12.71 | 79.9 | 16.23 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 18.25 | NA | -6.12 |
| R&D | 9.75 | NA | 8.07 |
| Normalized Inc. | 12.46 | NA | 16.04 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -1.1 | 1.3 | 17.3 |
| Earnings % | -21.0 | -23.7 | 24.2 |
| EPS % | -16.0 | -17.0 | 23.4 |
| EPS $ | -0.25 | -0.09 | 0.37 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 66.73 |
| Current Ratio | 13.5 |
| Quick Ratio (Acid Test) | 11.7 |
| Liquidity Ratio (Cash) | 10.88 |
| Receivables Turnover | 11.8 |
| Average Collection Period | 31 |
| Working Capital/Equity | 71.3 |
| Working Capital pS | 11.09 |
| Cash-Flow pS | 2.84 |
| Free Cash-Flow pS | 2.43 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 24.44 |
| Financial Leverage Ratio (Assets/Equity) | 1.1 |
| Debt Ratio | 6.4 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 1.1 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.00 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 1.23 |
| Tobin's Q Ratio | 2.39 |
| Current P/E Ratio - LTM | 25.00 |
| Enterprise Value (EV)/EBITDA | 8.71 |
| Enterprise Value (EV)/Free Cash Flow | 16.11 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 4.08 |
| Price/Book Ratio - LTM | 2.84 |
| Price/Cash Flow Ratio | 15.1 |
| Price/Free Cash Flow Ratio - LTM | -51.4 |
| Price/Sales Ratio | 4.43 |
| P/E Ratio (1 month ago) - LTM | 25.3 |
| P/E Ratio (26 weeks ago) - LTM | 23.0 |
| P/E Ratio (52 weeks ago) - LTM | 19.1 |
| 5-Y High P/E Ratio | 53.6 |
| 5-Y Low P/E Ratio | 15.4 |
| 5-Y Average P/E Ratio | 38.7 |
| Current P/E Ratio as % of 5-Y Average P/E | 65 |
| P/E as % of Industry Group | 55.0 |
| P/E as % of Sector Segment | 12.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 25.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 0.89 |
| Tangible Book Value pS - LTM | 10.37 |
| Book Value pS - LTM | 14.91 |
| Capital Invested pS | 16.58 |
| Cash pS - LTM | 3.19 |
| Cash Flow pS - LTM | 2.81 |
| Free Cash Flow pS - LTM | -0.82 |
| Earnings pS (EPS) | 1.95 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 26.85 |
| Free Cash Flow Margin 5YEAR AVG | 16.77 |
| Net Profit Margin | 22.6 |
| Net Profit Margin - 5YEAR AVRG. | 20.7 |
| Equity Productivity | 0.58 |
| Return on Equity (ROE) | 13.1 |
| Return on Equity (ROE) - 5YEAR AVRG. | 12.5 |
| Capital Invested Productivity | 0.58 |
| Return on Capital Invested (ROCI) | 13.1 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 12.5 |
| Assets Productivity | 0.60 |
| Return on Assets (ROA) | 12.3 |
| Return on Assets (ROA) - 5YEAR AVRG. | 11.5 |
| Gross Profit Margin | 80.1 |
| Gross Profit Margin - 5YEAR AVRG. | 80.5 |
| EBITDA Margin - LTM | 34.4 |
| EBIT Margin - LTM | 28.8 |
| Pre-Tax Profit Margin | 34.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 30.5 |
| Effective Tax Rate | 33.5 |
| Effective Tax Rate - 5YEAR AVRG. | 32.4 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 242 |
| Revenue per Employee | 476,988 |
| Net Income per Employee | 107,925 |
| Average Collection Period | 28 |
| Receivables Turnover | 11.8 |
| Day's Inventory Turnover Ratio | 214 |
| Inventory Turnover | 1.7 |
| Inventory/Sales | 11.5 |
| Accounts Payble/Sales | 3.40 |
| Assets/Revenue | 1.67 |
| Net Working Capital Turnover | 0.81 |
| Fixed Assets Turnover | 1.95 |
| Total Assets Turnover | 0.6 |
| Revenue per $ Cash | 7.86 |
| Revenue per $ Plant | 3.33 |
| Revenue per $ Common Equity | 0.58 |
| Revenue per $ Capital Invested | 0.58 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 20.8 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 21.9 |
| Research & Devlopment (R&D) as % of Revenue | 21.4 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 21.4 |
|
|  
|
| |
 |  |